Cytyc
This article was originally published in The Gray Sheet
Executive Summary
Chlamydia and gonorrhea testing directly from Cytyc ThinPrep Pap Test collection vial samples using Roche's Cobas Amplicor automated test system gains PMA supplement approval. Cytyc had indicated it would reevaluate a related October 2000 co-marketing agreement with Roche following its February agreement to purchase HPV test maker Digene, which also has chlamydia and gonorrhea testing technology. Roche announced June 6 that it will develop an HPV test to compete with Digene's, in a market expected to exceed $600 mil. by 2010, after acquiring HPV patents from Institut Pasteur. Ironically, the prospect of increased competition could simultaneously make the Digene purchase less attractive to Cytyc and more likely to receive anti-trust clearance, which is pending. Cytyc extended its offer for a sixth time on June 7, to June 21, following submission of requested information to FTC May 28 (1"The Gray Sheet" June 3, 2002, In Brief)...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.